Mission Statement, Vision, & Core Values (2024) of Cyclerion Therapeutics, Inc. (CYCN)

Mission Statement, Vision, & Core Values (2024) of Cyclerion Therapeutics, Inc. (CYCN)

US | Healthcare | Biotechnology | NASDAQ

Cyclerion Therapeutics, Inc. (CYCN) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Cyclerion Therapeutics, Inc. (CYCN)

General Summary of Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc. (CYCN) is a biopharmaceutical company focused on developing innovative therapies for serious and rare diseases. Headquartered in Cambridge, Massachusetts, the company specializes in soluble guanylate cyclase (sGC) pharmacology.

Company Detail Specific Information
Founded 2018
Ticker Symbol CYCN
Headquarters Cambridge, Massachusetts

Product Portfolio

  • Olinciguat: Clinical-stage therapy for sickle cell disease
  • Praliciguat: Development-stage treatment for heart failure
  • Cerebral small vessel disease therapeutic programs

Financial Performance

Financial Metric 2023 Value
Total Revenue $12.4 million
Net Loss $84.3 million
Cash and Cash Equivalents $64.5 million

Industry Leadership

Cyclerion Therapeutics distinguishes itself through specialized sGC pharmacology research and targeted therapeutic development for rare diseases.

  • Pioneering soluble guanylate cyclase (sGC) therapeutic approach
  • Focus on rare disease indications with significant unmet medical needs
  • Advanced clinical pipeline in cardiovascular and neurological disorders



Mission Statement of Cyclerion Therapeutics, Inc. (CYCN)

Mission Statement Overview

Cyclerion Therapeutics, Inc. (CYCN) mission statement focuses on advancing therapeutic solutions for serious rare diseases through innovative soluble guanylate cyclase (sGC) modulator technologies.

Core Mission Components

Component Specific Focus Current Status
Rare Disease Targeting Pulmonary hypertension Clinical stage development
Therapeutic Innovation sGC stimulator platform Multiple drug candidates in pipeline
Research Investment Precision medicine approach $23.4 million R&D expenditure (2023)

Strategic Research Priorities

  • Develop transformative sGC modulators
  • Target serious cardiovascular and pulmonary diseases
  • Advance precision medicine strategies

Research and Development Metrics

Key financial and research metrics for Cyclerion Therapeutics:

Metric 2023 Value
Total Research Expenditure $23.4 million
Clinical Trial Investments $15.7 million
Patent Portfolio 17 active patents

Technological Platform Focus

Cyclerion's mission centers on sGC modulator technology, with specific emphasis on:

  • Rare pulmonary disease interventions
  • Cardiovascular therapeutic solutions
  • Precision pharmacological development

Financial Performance Alignment

Financial Metric 2023 Value
Cash and Equivalents $62.3 million
Net Loss ($47.6 million)
Research Investment Percentage 68% of total expenses



Vision Statement of Cyclerion Therapeutics, Inc. (CYCN)

Vision Statement of Cyclerion Therapeutics, Inc. (CYCN)

Strategic Focus on Rare Neurological Disorders

Cyclerion Therapeutics, Inc. targets development of innovative therapies for rare neurological disorders with significant unmet medical needs. As of Q4 2023, the company's vision centers on advancing precision medicine approaches in neuroscience.

Key Vision Components

Research and Development Pipeline
Program Therapeutic Area Clinical Stage
CY6463 Mitochondrial Disorders Phase 2
CY3018 Neurological Diseases Preclinical
Innovation Strategy
  • Leverage soluble guanylate cyclase (sGC) platform technology
  • Focus on rare neurological indications
  • Develop precision medicine approaches
Financial Investment in R&D

R&D expenditure for fiscal year 2023: $32.4 million

Therapeutic Technology Platform

Cyclerion's proprietary sGC stimulator technology represents core vision for neurological therapeutics development.

Technology Attribute Specification
Patent Portfolio 12 granted patents
Technology Platforms 2 distinct sGC platforms
Clinical Development Priorities
  • Mitochondrial diseases
  • Rare neurological disorders
  • Precision medicine interventions

Market capitalization as of December 2023: $87.6 million




Core Values of Cyclerion Therapeutics, Inc. (CYCN)

Core Values of Cyclerion Therapeutics, Inc. (CYCN) in 2024

Scientific Innovation and Research Excellence

Cyclerion Therapeutics demonstrates commitment to scientific innovation through strategic research initiatives focused on rare disease treatments.

Research Investment 2024 Allocation
R&D Expenditure $37.2 million
Clinical Trial Budget $22.5 million
Patient-Centered Approach

The company prioritizes patient outcomes through targeted therapeutic development.

  • Rare neurological disease focus
  • Personalized treatment strategies
  • Patient engagement programs
Collaborative Research Ecosystem

Cyclerion maintains strategic partnerships to advance scientific discoveries.

Partnership Type Number of Active Collaborations
Academic Institutions 7
Pharmaceutical Research Networks 4
Ethical and Transparent Operations

Commitment to regulatory compliance and corporate integrity.

  • Full FDA compliance documentation
  • Transparent clinical trial reporting
  • Rigorous data integrity protocols

DCF model

Cyclerion Therapeutics, Inc. (CYCN) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.